SCHEMBL1365004

SCHEMBL1365004

C[C@H](O)[C@@H](Nc1ccc(C#N)c2ccccc12)C(=O)NNC(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.36
CTSL P07711 5/20 0.35
CTSS P25774 2/20 0.35
CTSB P07858 1/20 0.35
CTSK P43235 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC22A12 Q96S37 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
CFTR P13569 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3430808 1.00 L3MBTL1 (0.36) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL1365748 1.00 L3MBTL1 (0.36) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL1363199 0.93 MAOA (0.39) L3MBTL1NPC1RAB9A
SCHEMBL1365002 0.86 CXCR1 (0.38) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL12140344 0.86 CXCR1 (0.38) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL12140312 0.86 CXCR1 (0.38) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL12306450 0.86 L3MBTL1 (0.35) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL1363809 0.86 RAB9A (0.34) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL1364446 0.86 RAB9A (0.34) L3MBTL1CTSLCTSSCTSBCTSK
SCHEMBL1365319 0.84 AR (0.43) L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2260028-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2014-05-07 EP disclosed
EP-2260028-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2014-05-07 EP disclosed
US-8629167-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2014-01-14 US disclosed
US-8629167-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2014-01-14 US disclosed
US-8455525-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2013-06-04 US disclosed
US-8455525-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2013-06-04 US disclosed
US-20130116288-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. (US) 2013-05-09 US disclosed
US-20130116288-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. (US) 2013-05-09 US disclosed
US-8268872-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2012-09-18 US disclosed
US-8268872-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2012-09-18 US disclosed
US-8067448-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2011-11-29 US disclosed
US-20110224267-A1 Selective androgen receptor modulators Radius Health,Inc. (US) 2011-09-15 US disclosed
US-20110224267-A1 Selective androgen receptor modulators Radius Health,Inc. (US) 2011-09-15 US disclosed
EP-2260028-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2010-12-15 EP disclosed
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2010-02-18 US disclosed
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2010-02-18 US disclosed
US-20090253758-A1 Selective androgen receptor modulators ELLIPSES PHARMA LTD (GB) 2009-10-08 US disclosed
US-20090253758-A1 Selective androgen receptor modulators ELLIPSES PHARMA LTD (GB) 2009-10-08 US disclosed
WO-2009105214-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2009-08-27 WO disclosed
WO-2009105214-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, IGF1R L3MBTL1 4785/4885CTSL 4753/4885CTSS 4856/4885
US-20110224267-A1 Selective androgen receptor modulators AR, SHBG, GPR119 L3MBTL1 4804/4885CTSL 4766/4885CTSS 4862/4885
US-20130116288-A1 Selective Androgen Receptor Modulators AR, SHBG, IGF1R L3MBTL1 4758/4885CTSL 4781/4885CTSS 4862/4885
US-20090253758-A1 Selective androgen receptor modulators AR, SHBG, GPR119 L3MBTL1 4804/4885CTSL 4766/4885CTSS 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.